TABLE 1.
Clinicopathologic and Treatment Characteristics Among Patients Undergoing Post-NAC MRI vs Clinical Exam Alone
| Variable | Clinical exam + MRI (n = 182) | Clinical exam only (n = 87) | p-value |
|---|---|---|---|
| Age, median (range) | 50 (24-77) | 49 (28-82) | 0.98 |
| BMI, median (range) | 26 (18-48) | 26 (17-47) | 0.36 |
| Tumor type | 0.2 | ||
| IDC | 174 (96%) | 80 (92%) | |
| ILC | 2 (1%) | 4 (5%) | |
| Mixed/other | 6 (3%) | 3(3%) | |
| Histologic grade | 0.2 | ||
| 1 | 1 (0.5%) | 0 (0%) | |
| 2 | 11 (6%) | 10 (11%) | |
| 3 | 168 (92%) | 74 (85%) | |
| N/A | 2 (1%) | 3 (3%) | |
| LVI | 0.63 | ||
| Yes | 78 (43%) | 42 (48%) | |
| No | 73 (40%) | 30 (34%) | |
| Suspicious | 8 (4%) | 4 (5%) | |
| N/A | 23 (13%) | 11 (13%) | |
| Clinical T | 0.47 | ||
| Tis/x | 1 (0.5%) | 2 (2%) | |
| T1 | 31 (17%) | 15 (17%) | |
| T2 | 109 (60%) | 47 (54%) | |
| T3 | 41 (23%) | 23 (26%) | |
| Subtype | 0.14 | ||
| ER+/HER2− | 60 (33%) | 40 (46%) | |
| ER+/HER2+ | 43 (24%) | 14 (16%) | |
| ER−/HER2+ | 28 (15%) | 15 (17%) | |
| ER−/HER2− | 51 (28%) | 18 (21%) | |
| NAC type | 0.75 | ||
| ACT based | 175 (96%) | 83 (95%) | |
| Other | 7 (4%) | 4 (5%) | |
| Type of surgery | <0.001 | ||
| Lumpectomy | 98 (54%) | 14 (16%) | |
| Mastectomy | 84 (46%) | 73 (84%) | |
| Number of SLN removed Median, (range) | 4 (1-13) | 4 (0-14) | 0.4 |
| Sentinel node status | |||
| Positive | 85 (47%) | 45 (52%) | 0.5 |
| Negative | 97 (53%) | 42 (48%) |
NAC neoadjuvant chemotherapy, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, N/A not available, LVI lymphovascular invasion, ER estrogen receptor, ACT doxorubicin plus cyclophosphamide followed by weekly paclitaxel, SLN sentinel lymph node